DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Tewari KS, Sill MW, Penson RT. et al.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Lancet 2017;
390: 1654-1663
DOI: 10.1016/S0140-6736(17)31607-0.
We do not assume any responsibility for the contents of the web pages of other providers.